Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Veterinary dermatology in 2026 evaluated comparative Efficacy and Safety of Adjunctive 0.015% Triamcinolone Acetonide Topical Spray With Lokivetmab Versus Lokivetmab Monotherapy as 'Reactive Therapy' for Canine Atopic Dermatitis: A Randomised, Single-Blinded, Controlled Preliminary Trial..
Key Findings
Lokivetmab is considered an effective systemic therapy for dogs with atopic dermatitis (AD); however, utilisation of lokivetmab with adjunctive topical anti-inflammatory glucocorticoids has not been investigated in canine AD. To evaluate the efficacy and safety of the combination therapy of lokivetmab and 0.015% triamcinolone acetonide (TCA) spray in dogs with AD. Twenty dogs with nonseasonal AD. This study was a randomised, single-blinded (investigators only) 4-week controlled trial. Dogs were randomised to receive lokivetmab monotherapy or lokivetmab-TCA spray per manufacturer instructions. Clinical assessments included the Canine Atopic...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
List
Add
Please enter a comment